The use of F919 class compounds, their salts, and stereoisomers in the preparation of anti-hepatocellular carcinoma drugs and anti-cancer drugs.
By developing F919-class compounds to prepare anti-liver cancer drugs, the problem of poor efficacy of existing drug treatments has been solved, achieving highly efficient inhibition and tumor suppression of liver cancer cells, and providing a new targeted therapy option.
Patent Information
- Application Number
- CN202411416929.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-11
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-10-11
AI Technical Summary
Existing anti-liver cancer drugs are ineffective and prone to drug resistance, resulting in extremely poor prognosis for liver cancer patients. There is a lack of effective targeted therapies.
F919-class compounds and their salts and stereoisomers were developed for the preparation of anti-hepatocellular carcinoma drugs. These drugs exhibit significant antitumor activity against hepatocellular carcinoma cells by inhibiting cell cycle proliferation, inducing cell cycle arrest and apoptosis, and affecting the expression of related proteins.
F919-type compounds can effectively inhibit the proliferation of liver cancer cells, arrest cell cycle progression, induce apoptosis, and significantly inhibit the growth of liver cancer in situ in nude mouse models, providing a new targeted therapy.
Smart Images

Figure CN119285578B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to the use of F919 class compounds and their salts and stereoisomers in the preparation of anti-liver cancer drugs and anti-cancer drugs. Background Technology
[0002] Liver cancer is one of the leading causes of death from malignant tumors. Because the liver is located in a relatively hidden area, and early symptoms of liver cancer are often only manifested as common digestive system disorders such as loss of appetite, fatigue, and nausea, they are easily overlooked. Currently, early liver cancer screening mainly relies on serum alpha-fetoprotein (AFP) and abdominal ultrasound examination. However, the sensitivity, specificity, and predictive value of AFP testing are still controversial in the academic community. Furthermore, asymptomatic patients typically do not actively seek medical attention for ultrasound examinations. In addition, liver cancer is highly malignant, with a high rate of metastasis and recurrence, leading to most patients being diagnosed at an intermediate or advanced stage, requiring drug treatment. However, currently available anti-liver cancer drugs have unsatisfactory treatment effects, and most systemic therapies develop drug resistance, resulting in extremely poor prognoses for liver cancer patients. Therefore, drug treatment for liver cancer patients is a major clinical challenge. Thus, developing novel anti-liver cancer drugs has significant theoretical and practical value for improving the prognosis of liver cancer patients.
[0003] The goal of new drug development is to create high-quality drugs that are more effective than existing therapies in preventing, diagnosing, treating, and / or alleviating symptoms. In recent years, with the rapid development of new research methods such as high-throughput sequencing, researchers have begun to focus on using tumor biomarkers to guide the early clinical development of anti-tumor drug candidates, thereby reducing the risk of drug development failure. The successful market launch of epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, and immune checkpoint inhibitors in emerging immunotherapies are all based on in-depth research into tumor biomarkers in basic research. Research on the application of amides in liver cancer is still in the development stage. Currently, there are relatively few types of amides used in liver cancer, and the role of F919 compounds, which are amides, in liver cancer has not been studied. Summary of the Invention
[0004] To address the aforementioned technical problems, this invention provides the use of F919 class compounds and their salts and stereoisomers in the preparation of anti-liver cancer drugs, as well as anti-cancer drugs.
[0005] The use of F919 class compounds in the preparation of anti-liver cancer drugs, wherein the structural formula of the F919 class compounds is as follows:
[0006]
[0007] Wherein, R1 is a C1-C6 alkyl group or a halogen;
[0008] R2 is a thiophene ring, a benzene ring, a halogen-substituted benzene ring, or an alkyl-substituted benzene ring.
[0009] Preferably, the structural formula of the F919 type compound is as follows: formula (1), formula (2), formula (3) or formula (4):
[0010]
[0011] Preferably, the anti-liver cancer drug comprises one or more compounds having the structural formulas of (1), (2), (3), and (4) described above.
[0012] Preferably, the anti-liver cancer drug is a drug that inhibits the proliferation of liver cancer cells and reduces the ability of liver cancer cell clones to form.
[0013] Preferably, the anti-liver cancer drug is a drug that induces cell cycle arrest and apoptosis in liver cancer cells.
[0014] Preferably, the anti-liver cancer drug is a drug that affects the expression of proteins related to the cell cycle process of liver cancer cells.
[0015] Preferably, the anti-liver cancer drug is a drug that has tumor-suppressing activity against nude mouse orthotopic tumors of liver cancer cells.
[0016] An anti-liver cancer drug comprising any of the compounds described herein, or their salts, or their stereoisomers.
[0017] Preferably, the drug also includes pharmaceutically acceptable excipients.
[0018] Preferably, the pharmaceutically acceptable excipient is sterile water for injection or sodium chloride injection.
[0019] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0020] The compounds of this invention can efficiently inhibit the proliferation of human hepatocellular carcinoma cells, induce G0 / G1 phase cell cycle arrest and apoptosis in hepatocellular carcinoma cells, and exhibit significant antitumor activity against nude mouse orthotopic tumors of hepatocellular carcinoma cells. This invention provides a new class of drugs for the treatment of hepatocellular carcinoma and offers an effective method for developing targeted therapies for hepatocellular carcinoma, which is of great significance for the preparation of drugs for treating hepatocellular carcinoma. Attached Figure Description
[0021] Figure 1Figure 1 shows the effects of different compounds on the viability of L02 and MHCC97-H cells. A shows the effect of F919-1131 on the viability of L02 and MHCC97-H cells as detected by CCK-8 assay; B shows the effect of F919-1171 on the viability of L02 and MHCC97-H cells as detected by CCK-8 assay; C shows the effect of F919-1187 on the viability of L02 and MHCC97-H cells as detected by CCK-8 assay; D shows the effect of F919-1172 on the viability of L02 and MHCC97-H cells as detected by CCK-8 assay; E shows the effect of sorafenib on the viability of L02 and MHCC97-H cells as detected by CCK-8 assay.
[0022] Figure 2 Figure A shows the effect of F919-1172 on the colony-forming ability and apoptosis of MHCC97-H cells, as detected by the colony-forming assay. Figure B shows the effect of F919-1172 on the colony-forming ability of MHCC97-H cells as detected by flow cytometry.
[0023] Figure 3 Figure A shows the effect of F919-1172 on the cell cycle progression of MHCC97-H cells; Figure B shows the effect of F919-1172 on the cell cycle of MHCC97-H cells detected by flow cytometry; Figure C shows the effect of F919-1172 on the expression of G1 / S cell cycle checkpoint-related proteins in MHCC97-H cells detected by Western blot; Figure C shows the statistical analysis of the expression levels of different G1 / S cell cycle checkpoint-related proteins in MHCC97-H cells.
[0024] Figure 4 Figure A shows the effect of F919-1172 on the proliferation of orthotopic liver cancer tumors in nude mice. Figure B is a schematic diagram of the orthotopic liver cancer tumor experiment in nude mice. MHCC97-H-Luc cell orthotopic liver cancer tumor models were constructed in 5-6 week old female nude mice. On day 7 after modeling, tumor size was measured using in vivo imaging and the mice were grouped. Initially, high- and low-dose F919-1172 or sorafenib were administered intraperitoneally every two days, and the mice were weighed. The nude mice were anesthetized and sacrificed on day 22. Figure C shows the bioluminescence image of orthotopic liver cancer tumors in nude mice. Figure C shows the fluorescence intensity statistics of orthotopic liver cancer tumors in nude mice. Figure D shows images of the liver and intrahepatic tumors of nude mice. Figure E shows the expression of the proliferation marker Ki-67 protein in the liver tissue of each group of nude mice using immunohistochemical staining. The left side of the dotted line represents adjacent normal tissue, and the right side represents tumor tissue. Figure F shows the weight statistics of the nude mice.
[0025] Figure 5 Figure showing the effects of HE staining on the heart, spleen, lung, kidney, and brain tissues of nude mice. Detailed Implementation
[0026] The specific embodiments of the present invention are described in detail below, but it should be understood that the scope of protection of the present invention is not limited to the specific embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention. Unless otherwise specified, the experimental methods described in the embodiments of the present invention are conventional methods.
[0027] In this invention, solutions of F919 compounds at different concentrations are prepared using sterile water for injection as a solvent.
[0028] Example 1: Cell Culture: Human hepatocellular carcinoma cell line MHCC97-H was cultured in high-glucose DMEM complete medium, and human normal hepatocyte cell line L02 was cultured in RPMI 1640 complete medium. The incubator temperature was kept constant at 37°C, and the CO2 concentration was kept constant at 5% (v / v). The high-glucose DMEM complete medium contained 10% fetal bovine serum and 1% penicillin / streptomycin (v / v), and the RPMI 1640 complete medium contained 10% fetal bovine serum and 1% penicillin / streptomycin (v / v).
[0029] Example 2: Detection of the effect of F919 class small molecule compounds on the proliferation ability of human hepatocellular carcinoma cells and normal hepatocytes
[0030] The structures of the F919 class small molecule compounds described in this invention are shown in formulas (1), (2), (3), and (4):
[0031]
[0032] Equation (1) is denoted as F919-1131; Equation (2) is denoted as F919-1171; Equation (3) is denoted as F919-1187; Equation (4) is denoted as F919-1172.
[0033] The cell subjects used in the experiment included human hepatocellular carcinoma cells MHCC97-H and normal human hepatocytes L02. After treating various cell types with different concentrations of F919-type compounds and the positive control drug sorafenib for 48 hours, the original culture medium was discarded, and 90 μL of culture medium and 10 μL of CCK-8 were added to each well. The cells were then incubated in an incubator for 40 min, and the OD value was detected at 450 nm using a microplate reader.
[0034] The results of the CCK-8 experiment are as follows: Figure 1 As shown, the results revealed that, compared with the solvent group, F919 compounds significantly inhibited the proliferation of human hepatocellular carcinoma MHCC97-H cells, but had a smaller inhibitory effect on the proliferation of normal hepatocytes L02.
[0035] Example 3: Detection of the effect of F919-1172 on the clonogenic ability of human hepatocellular carcinoma cells
[0036] The cancer cells used in the experiment were human hepatocellular carcinoma cells MHCC97-H. Cells were treated with compound F919-1172 for 14 days, then the original culture medium was discarded. The culture medium containing F919-1172 was replaced every 72 hours over the 14 days. Cells were washed three times with PBS, and 1 mL of 4% paraformaldehyde was added to each well for fixation for 40 min. Cells were then washed three times with PBS, and 1 mL of crystal violet staining solution was added to each well for staining for 10 min. After washing three times with PBS and air-drying, the entire six-well plate and each well were photographed individually using a digital camera.
[0037] It should be noted that similar results can be achieved by fixing cells with 4% paraformaldehyde for 30 to 60 minutes or staining them with crystal violet for 10 to 20 minutes.
[0038] Results of cell plate colony formation experiment as follows Figure 2 As shown in Figure A, the results showed that, compared with the solvent group, the number of human liver cancer MHCC97-H cell clones formed in the F919-1172-treated group was significantly reduced, indicating that F919-1172 can inhibit the cell clone formation ability of liver cancer cell lines.
[0039] Example 4: Detection of apoptosis level in human hepatocellular carcinoma cells after treatment with F919-1172
[0040] The cancer cells used in the experiment were human liver cancer cells MHCC97-H.
[0041] Flow cytometry assay for apoptosis: Cells were seeded in 6-well plates and treated with different concentrations of F919-1172. After 48 hours, the cell supernatant was aspirated and collected in centrifuge tubes. Cells were washed three times with PBS, digested with trypsin, and collected in EP tubes containing supernatant. The cells were centrifuged at 1000 rpm for 10 min at 4°C, the supernatant was discarded, 500 μL of binding buffer was added, and the cells were gently pipetted to prepare a cell suspension. The cell count was adjusted to 5 × 10⁶ cells / well. 5 Cells / mL; aspirate 195 μL of cell resuspension and transfer to a 1.5 mL EP tube; add 5 μL of Annexin V-FITC staining solution to each group, mix well, and then add 10 μL of PI staining solution; protect from light, let stand for 15 min, and then perform instrumental analysis.
[0042] Experimental results are as follows Figure 2As shown in Figure B, in MHCC97-H cells, the apoptotic percentage was 6.79% ± 0.35% in the solvent control group, 9.31% ± 0.21% in the F919-1172 25 μM group, 13.03% ± 0.33% in the F919-1172 10 μM group, and 26.07% ± 0.38% in the F919-1172 20 μM group, all significantly higher than that in the solvent control group. These results indicate that F919-1172 can induce apoptosis in MHCC97-H cells.
[0043] Example 5: Detection of cell cycle and cell cycle-related protein expression in human hepatocellular carcinoma cells treated with F919-1172
[0044] The cancer cells used in the experiment were human liver cancer cells MHCC97-H.
[0045] I. Cell Cycling Assay: Cells were seeded in 6-well plates and treated with different concentrations of F919-1172. After 48 hours, the cell supernatant was collected, and the cells were digested with trypsin and collected in 1.5 mL EP tubes. The cells were centrifuged at 1000 rpm for 10 min at 4°C, the supernatant was discarded, and the cells were washed twice with PBS. 1 mL of pre-chilled 70% ethanol was added to each tube, and the cells were dispersed and fixed at 4°C for 24 hours. The cells were centrifuged at 1000 rpm for 5 min, and the supernatant was discarded. 1 mL of pre-chilled PBS was added to each tube, and the cells were washed twice, and the supernatant was discarded. 500 μL of propidium iodide staining solution was added to each tube to resuspend the cells, and the cells were incubated at 37°C in the dark for 30 min. Fluorescence and light scattering were detected by flow cytometry at a wavelength of 488 nm.
[0046] Experimental results are as follows Figure 3As shown in Figure A, in MHCC97-H cells, the proportion of cells in the G0 / G1 phase in the solvent control group was 46.06% ± 1.02%, while the proportion of cells in the G0 / G1 phase in the F919-117 210μM group was 59.63% ± 2.61%, and the proportion of cells in the G0 / G1 phase in the F919-117 220μM group was 63.78% ± 0.71%, all significantly higher than that in the solvent control group; the proportion of cells in the S phase in the solvent control group was 30.60% ± 0.80%, and the proportion of cells in the S phase in the F919-117 210μM group was significantly higher. The percentage of cells in the S phase in the F919-1172 20μM group was 19.08% ± 1.33%, and the percentage of cells in the S phase in the F919-1172 20μM group was 16.84% ± 0.94%, both significantly lower than those in the solvent control group. The percentage of cells in the G2 / M phase in the solvent control group was 13.14% ± 1.06%, in the F919-1172 210μM group it was 13.71% ± 0.73%, and in the F919-1172 220μM group it was 12.55% ± 1.16%, all without significant difference compared to the solvent control group. These results indicate that F919-1172 can inhibit the transition of MHCC97-H cells from the G0 / G1 phase to the S phase, thus arresting cell cycle progression.
[0047] II. Western blotting assay for cell cycle-related proteins: Cells were seeded at 60 mm... 2 Different concentrations of F919-1172 were applied to culture dishes. Cells were collected after 48 hours and Western blotting experiments were performed as follows.
[0048] Perform Western blotting experiments as follows:
[0049] 1. Protein extraction
[0050] (1) Cell preparation: Scrape cells with a cell scraper, transfer the cells with culture medium to a 15mL centrifuge tube, centrifuge at 1000rpm for 10min to collect the cell pellet, wash and resuspend the cells twice with PBS; add an appropriate amount of RIPA cell lysis buffer, transfer to a 1.5mL EP tube, RIPA cell lysis buffer contains protease inhibitors and phosphatase inhibitors.
[0051] (2) Cell disruption: Cells were disrupted on ice for 3 seconds at 15% power using a cell sonic disruptor, followed by 3 seconds of cooling. This process was repeated 3 times. After lysis, cells were placed on ice for 30 minutes, followed by centrifugation at 12,000 rpm for 20 minutes at 4°C. The supernatant was carefully aspirated into a clean, pre-cooled new EP tube.
[0052] 2. Protein quantification, abbreviated as BCA method
[0053] (1) Preparation of standard curves: BSA standard solutions of 2 mg / mL, 1 mg / mL, 0.5 mg / mL, 0.25 mg / mL, 0.125 mg / mL and 0 mg / mL were prepared using RIPA cell lysis buffer.
[0054] (2) Preparation of colorimetric solution: Thermo Fisher Scientific BCA quantitative reagent kit was used to prepare the colorimetric solution according to the ratio of A:B = 50:1.
[0055] (3) Sample addition: Add 10 μL of sample and 10 μL of different concentration standards to each well of the 96-well plate, and immediately add 200 μL of AB colorimetric solution. Incubate at 37°C for 30 min.
[0056] (4) Concentration determination: Protein concentration was measured at 562nm wavelength using an enzyme-linked immunosorbent assay (ELISA) reader. Based on the measured absorbance value of the standard, RIPA cell lysis buffer and 5× loading buffer were added to adjust the cell concentration to be consistent.
[0057] (5) Protein denaturation: Heat in a metal bath for 10 minutes to fully denature the protein, and store in a -20°C refrigerator.
[0058] 3. Gel preparation: Depending on the molecular weight of the protein, a lower separating gel with a volume concentration of 6% to 15% and an upper stacking gel with a volume concentration of 5% need to be prepared.
[0059] (1) Install the glass plate: The glass plate should be cleaned and dried in the oven in advance. When installing, make sure that the bottom ends are aligned on the same plane, otherwise the glue will leak. Fix the glass plate on the bracket and clamp it for later use.
[0060] (2) Prepare the lower layer separating gel: Prepare the required gel according to the formula, quickly pour the mixed gel into the groove of the glass plate, add 2mL of deionized water, flatten the separating gel, and let it stand for 40min.
[0061] (3) Prepare the upper layer of gel: After the lower layer of gel has solidified, pour off the deionized water, drain the liquid, gently absorb the residual liquid with filter paper, pour in the upper layer of gel, insert a comb between the two glass plates, and let stand for 30 minutes.
[0062] (4) Protein loading: Take the protein sample out of -20℃ and place it on ice immediately. Determine the loading volume according to the protein concentration, so that the loading amount is generally 20μg.
[0063] (5) Electrophoresis: When running the upper gel, keep the voltage constant at 80V and electrophore for 30 minutes; when running the lower gel, keep the voltage constant at 120V and electrophore for 60 minutes to fully separate the marker bands corresponding to the target bands. It should be noted that electrophoresis for 60 minutes to 80 minutes can achieve similar results.
[0064] (6) Transfer: Activate the PVDF membrane in methanol for 30 seconds, cut off the top layer of adhesive, install the transfer device, blackboard (-) → porous padding sponge → second layer of filter paper → gel → PVDF membrane → second layer of filter paper → porous padding sponge → whiteboard (+), carefully remove air bubbles between each layer, put the transfer device into the transfer tank, add the transfer solution, put an ice box in the empty space in the transfer tank, close the lid, put the transfer tank into the foam box, fill it with ice water mixture, turn on the power, constant voltage 100V, transfer for 1 hour. It should be noted that similar effects can be achieved by transferring for 1 hour to 2 hours.
[0065] (7) Blocking: Prepare a 5% blocking solution using TBST and skim milk powder, and block for 1.5 hours.
[0066] (8) Primary antibody incubation: Remove the PVDF membrane, wash thoroughly with TBST blocking buffer, and add diluted target protein antibody. Primary antibodies: cyclin D1 (manufacturer: CST, dilution ratio: 1:1000); cyclin E1 (manufacturer: CST, dilution ratio: 1:1000); CDK2 (manufacturer: CST, dilution ratio: 1:1000); CDK4 (manufacturer: CST, dilution ratio: 1:1000); P21 (manufacturer: CST, dilution ratio: 1:1000); P27 (manufacturer: CST, dilution ratio: 1:1000); β-actin (manufacturer: Proteintech, dilution ratio: 1:5000). Incubate overnight at 4℃. Remove the PVDF membrane and wash it three times with room temperature TBST on a shaker for 10 min each time.
[0067] (9) Secondary antibody incubation: Place the PVDF membrane into the antibody incubation box, add the secondary antibody corresponding to the target protein antibody, the secondary antibody: Anti-Mouse IgG, manufacturer: Zhuangzhi Bio, dilution ratio: 1:5000; Anti-Rabbit IgG, manufacturer: Zhuangzhi Bio, dilution ratio: 1:5000, incubate at room temperature on a shaker for 1.5h; remove the PVDF membrane, wash it 3 times with TBST at room temperature on a shaker, 10min each time.
[0068] (10) Gel imaging luminescence: Prepare the luminescent solution, A:B = 1:1, mix well, and protect from light. Remove residual liquid with filter paper, immerse the PVDF membrane in the black box, and perform imaging with full contact.
[0069] Experimental results are as follows Figure 3As shown in B and C, after treatment with F919-1172, the expression levels of cyclin D1, cyclin E1, CDK2, and CDK4 proteins in MHCC97-H cells were significantly reduced, while the expression levels of P21 and P27 proteins were significantly increased. These results indicate that F919-1172 can inhibit the proliferation of human hepatocellular carcinoma MHCC97-H cells by affecting the expression of G1 / S cell cycle checkpoint-related proteins, thereby arresting cell cycle progression.
[0070] Example 6: Investigating the tumor-suppressing ability of F919-1172 in nude mice
[0071] The cancer cells used in the experiment were human hepatocellular carcinoma cells MHCC97-H. Thirty 5-6 week old female BALB / c nude mice were used as experimental animals, and the experiment lasted for 25 days. The study investigated the ability of F919-1172 to inhibit the growth of MHCC97-H in situ tumors in nude mice and its toxic effects on nude mice.
[0072] 1. Nude mouse liver in situ tumorigenesis experiment: Cells were collected when the cell healing rate reached 80%. It should be noted that cells can be collected when the cell healing rate reaches 80%-90%. The cells were washed three times with pre-cooled PBS to remove residual serum. After complete digestion with warm trypsin, digestion was stopped with complete culture medium. The cells were centrifuged at 1000 rpm for 10 min, and the supernatant was discarded. The cells were resuspended in a 1:1 mixture of matrix gel and serum-free culture medium, and the cell suspension concentration was adjusted to 1×10⁻⁶. 8Cells / mL. Nude mice were anesthetized by intraperitoneal injection of 4% chloral hydrate, with 10 mg of chloral hydrate per kg of body weight during anesthesia. The mice were fixed to the center of a foam board with their limbs fixed and abdomens facing upward. After disinfection with alcohol swabs, the abdominal skin and muscle layers were transversely incised below the xiphoid process using a disposable scalpel. The left lobe of the liver was carefully protruded with a cotton swab, and 20 μL of cell suspension was aspirated using a disposable insulin syringe and injected in situ into the liver. After injection, the muscle and skin tissue were sutured with disposable medical sutures, and the mice were placed on a 37°C constant temperature heating pad until they awoke. Seven days after the cell suspension injection, D-Luciferin at a concentration of 15 mg / mL was injected intraperitoneally at a dose of 10 μL / g. After 15 minutes, isoflurane gas anesthesia was performed using the gas anesthesia system of a live imaging instrument. The mice were then placed under the live imaging instrument for imaging, fluorescence observation, and tumor size calculation. Based on tumor size, the mice were divided into 4 groups of 5 mice each. Seven days after injection of the cell suspension, the experimental group received intraperitoneal injection every two days, while the control group received the same dose of solvent. In vivo imaging was performed every seven days. Three weeks later, blood was collected from the orbital cavity, and nude mice were euthanized by cervical dislocation. The animals were dissected using medical scissors and forceps to observe and photograph the liver tumor tissue. The heart, liver, spleen, lungs, kidneys, and brain were isolated and fixed in 4% paraformaldehyde for later use.
[0073] 2. Immunohistochemical staining: Dewax and rehydrate paraffin sections, perform antigen retrieval, and block with goat serum at room temperature for 1 hour after cooling. Place the sections face up on a glass slide, add 100 μL of primary antibody diluted with goat serum (Ki-67, Abcam, 1:200 dilution) to each slide, and incubate overnight at 4°C. Place the sections in a wash box and wash three times with PBS for 5 min each time. Add 100 μL of diluted secondary antibody (Anti-Rabbit, Zhuangzhi Bio, 1:100 dilution) and incubate at room temperature for 1 hour. Place the sections in a wash box and wash three times with PBS for 5 min each time. Mount the slides with mounting medium and observe and photograph under a microscope.
[0074] 3. HE staining: After fixation, the tissue is rinsed with running water for 2 hours, then dehydrated sequentially with 70%, 80%, and 90% ethanol solutions for 30 minutes each, followed by immersion in 95% and 100% ethanol solutions twice each for 20 minutes each. Next, it is immersed sequentially in a mixture of equal volumes of pure ethanol and xylene for 15 minutes, xylene I for 15 minutes, and xylene II for 15 minutes, until transparent. Then, it is placed in a 60℃ incubator with a mixture of equal parts xylene and paraffin for 15 minutes, followed by immersion in paraffin I and paraffin II for 50 minutes each. It should be noted that immersion in paraffin I and paraffin II for 50-60 minutes each can achieve similar results. A metal paraffin mold is picked up with tweezers, slightly heated over an alcohol lamp, and placed on a flat table. A wax cup containing pure paraffin is removed from the incubator, a small amount of paraffin is poured in, and then the tweezers... Slightly heat the material over an alcohol lamp, then place it cut-side down into the wax mold, arranging it neatly. Place the embedding cassette on top and gently pour in molten wax for embedding. Mount the fixed and trimmed paraffin block onto the stage of the microtome, and fix the microtome blade in the blade holder with the blade facing upwards. Shake the push screw to bring the paraffin block close to the blade. Adjust the angle and position between the paraffin block and the blade so that the blade and the paraffin section are at approximately a 15-degree angle. Adjust the thickness adjuster to achieve a section thickness of 5 μm. Place a 20 cm long strip of wax flat on the wax strip box, and use a single-edged blade to cut a small section of wax. Place it on a glass slide, add a drop of water, and observe the section under a microscope. Note that cutting the wax strip to 20 cm to 30 cm can achieve a similar effect. Take a clean glass slide, pick up the unfolded section, and position it at 1 / 3 of the section. Mark or label the ground surface and place it on the section holder.Adjust the water bath temperature to 60℃. Once the water temperature is controlled at 60℃, place the slides along with the slide holder into a dry staining jar, then place the jar in the water bath. Cover and incubate for 30 minutes until the wax melts. Next, sequentially immerse the slides in xylene for 10 minutes, then xylene for 10 minutes, then anhydrous ethanol for 5 minutes, then anhydrous ethanol for 5 minutes, then 95% ethanol for 5 minutes, then 90% ethanol for 5 minutes, then 80% ethanol for 5 minutes, then 70% ethanol for 5 minutes, then wash with distilled water. Next, stain the slides with Harris hematoxylin for 5 minutes, wash with tap water, differentiate with 1% hydrochloric acid ethanol for a few seconds, rinse with tap water, then restore blue color with 0.6% ammonia solution, and rinse with running water. Rinse with running tap water for about 15 minutes until the slides turn blue. Finally, immerse the slides in 1% hydrochloric acid ethanol solution to decolorize for about 2 seconds to several tens of seconds. The slide turns red, but the color should be light; then place the slide in running tap water to restore its blue color; immerse the slide in 50% ethanol, 70% ethanol, and 80% ethanol for 3 minutes each (3-5 minutes can achieve similar results); stain the slide in eosin solution for 3 minutes (1-3 minutes can achieve similar results); wash away excess red in 95% ethanol, then immerse in anhydrous ethanol for 3 minutes (3-5 minutes can achieve similar results), and finally blot away excess ethanol with absorbent paper; immerse the slide in xylene I and II for 3 minutes each (3-5 minutes can achieve similar results); mount in neutral resin, examine under a microscope, and acquire and analyze the images.
[0075] Experimental results are as follows Figure 4 As shown, compared with the solvent control group, treatment with high and low doses of F919-1172 and sorafenib significantly inhibited the growth of orthotopic liver cancer xenografts in nude mice. On day 22 after modeling, nude mice were anesthetized and sacrificed, and their livers were examined. The results showed that the livers of nude mice in the solvent control group were rich in tumor cells, while most livers in the high and low dose F919-1172 groups and the sorafenib group showed only a few tumor cells. Immunohistochemical staining of liver tissue under a microscope showed that the number of Ki-67-positive cells in the liver tumor tissues of nude mice in the high and low dose F919-1172 groups and the sorafenib group was significantly lower than that in the solvent control group. All experimental nude mice did not die during the experiment, and there was no significant difference in body weight among the groups. HE staining results are shown below. Figure 5 As shown, treatment with high and low doses of F919-1172 and sorafenib did not cause significant pathological changes in important tissues and organs such as the heart, spleen, lungs, kidneys, and brain in nude mice. These results indicate that F919-1172 can also exert anti-hepatocellular carcinoma activity in vivo and has good safety.
[0076] As can be seen from the above experiments, the F919-class small molecule compounds provided in the embodiments of the present invention can be used as targeted drugs, exhibiting highly effective inhibition of MHCC97-H cell proliferation, colony formation, cell cycle progression, and nude mouse orthotopic tumor growth, and inducing MHCC97-H cell apoptosis, thus having the potential for application in anti-tumor treatment, especially liver cancer treatment.
[0077] It should be noted that when numerical ranges are mentioned in the claims of this invention, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. To avoid redundancy, the present invention describes preferred embodiments.
[0078] Although preferred embodiments of the invention have been described, those skilled in the art, upon learning the basic inventive concept, can make other changes and modifications to these embodiments. Therefore, the appended claims are intended to be interpreted as including both the preferred embodiments and all changes and modifications falling within the scope of the invention.
[0079] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. Therefore, if these modifications and variations fall within the scope of the claims of this invention and their equivalents, this invention also intends to include these modifications and variations.
Claims
1. The use of F919 class compounds and their salts in the preparation of anti-hepatocellular carcinoma drugs, characterized in that: The structural formula of the F919 class of compounds is as follows (4): Equation (4): ; The aforementioned anti-liver cancer drugs are those that inhibit the proliferation of liver cancer cells and reduce the ability of liver cancer cell clones to form. The aforementioned anti-liver cancer drug is a drug that induces cell cycle arrest and apoptosis in liver cancer cells; The aforementioned anti-liver cancer drug is a drug that affects the expression of proteins related to the cell cycle process of liver cancer cells; The aforementioned anti-liver cancer drug is a drug that has tumor-suppressing activity against nude mouse orthotopic tumors of liver cancer cells.
2. An anti-liver cancer drug, characterized in that, It includes the compound described in claim 1 and pharmaceutically acceptable excipients.
Citation Information
Patent Citations
N-benzyl-3-phenylamide derivative, pharmaceutical composition containing same and application of N-benzyl-3-phenylamide derivative
CN115974766A
